Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows

Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows
Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to showing a 70 percent reduction in the risk of disease progression, the SOLO-2 Phase 3 trial (NCT01874353) revealed that Lynparza treatment did not reduce patients’

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *